Cochrane for Clinicians
Putting Evidence into Practice
Prophylactic Antibiotics for the Prevention of COPD Exacerbation
Am Fam Physician. 2014 Jun 1;89(11):870.
Author disclosure: No relevant financial affiliations.
Can prophylactic antibiotics decrease chronic obstructive pulmonary disease (COPD) exacerbations in a 67-year-old man with a history of frequent exacerbations?
Continuous prophylactic antibiotic therapy significantly decreases COPD exacerbations for up to three years. However, it does not decrease mortality, and it puts the patient at risk of antibiotic-resistant colonization and infection. (Strength of Recommendation: B, based on inconsistent or limited-quality patient-oriented evidence.)
COPD occurs in approximately 40% of smokers, affects more men than women, and is more common among those living in urban areas.1 The economic burden in the United States is as much as $49.5 billion annually, with most of this cost devoted to treating exacerbations.1 Current guidelines recommend preventive measures to limit exacerbations, including smoking cessation, immunization against pneumococcus and the influenza virus, maintenance therapy (e.g., use of inhaled steroids), and treatment of comorbid conditions.1
This systematic review analyzed seven randomized controlled trials involving 3,170 patients with a mean age of 66 years and at least moderate COPD. Patients were followed for three to 36 months. In five studies, patients were given continuous antibiotic therapy; in the other two, they received intermittent antibiotic therapy. All of the patients treated continuously were given macrolide antibiotics—azithromycin (Zithromax), clarithromycin (Biaxin), or erythromycin. Moxifloxacin (Avelox) was the only nonmacrolide antibiotic studied and was used only intermittently.
The number of patients with exacerbations was significantly reduced in those treated continuously (54% vs. 69% in the placebo group; number needed to treat = 8). Intermittent antibiotic use also reduced the number of exacerbations, but this result was not significant. Although continuous and intermittent regimens yielded a statistically significant improvement in quality of life, neither reduced important secondary outcomes such as frequency of hospital admission or all-cause mortality.
Adverse effects such as hearing loss were noted in patients taking azithromycin, and there was a statistically significant increase in the number of gastrointestinal symptoms among those taking moxifloxacin. Notably, patients treated with moxifloxacin experienced rapid development of antibiotic-resistant Pseudomonas infections.
The authors of this Cochrane review are hesitant to recommend continuous antibiotic therapy for all patients with COPD, given the cost, risks to each individual patient, and potential for increasing antibiotic resistance. In January 2014, the Global Initiative for Chronic Obstructive Lung Disease released updated guidelines on the management and prevention of COPD. These guidelines do not advocate use of prophylactic antibiotics.1 Although the use of prophylactic antibiotic regimens to prevent exacerbations shows promise, for now they should be used only for carefully selected patients (e.g., those with frequent exacerbations), if at all.
The practice recommendations in this activity are available at http://summaries.cochrane.org/CD009764.
Herath SC, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2013;(11):CD009764.
1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of COPD. 2014. http://www.goldcopd.org/. Accessed April 15, 2014.
These are summaries of reviews from the Cochrane Library.
The series coordinator for AFP is Corey D. Fogleman, MD, Lancaster General Hospital Family Medicine Residency, Lancaster, Pa.
A collection of Cochrane for Clinicians published in AFP is available at https://www.aafp.org/afp/cochrane.
Copyright © 2014 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Sep 15, 2018
Access the latest issue of American Family Physician